|  | Cancer | Lymphoma

Follicular Lymphoma: The "Watch and Wait" Strategy Explained

Watch and Wait (W&W)—active surveillance without immediate therapy—is standard for asymptomatic advanced-stage follicular lymphoma (FL). It spares toxicity without compromising survival.

Why W&W Is Appropriate

  • Indolent Natural History: Median survival >15–20 years; many never need treatment.
  • No Survival Benefit to Early Treatment: Multiple RCTs (e.g., Ardeshna, UK LG1) show equivalent OS for early vs. delayed treatment.
  • Treatment Toxicity: Chemoimmunotherapy causes cytopenias, neuropathy, secondary malignancies, infertility, fatigue — deferred until necessary.
  • Preserves Future Options: Avoids resistance; maintains fitness for novel agents.

W&W Protocol

  • Visits every 3–6 months: history, exam, CBC, LDH, β2-microglobulin.
  • Imaging: CT every 6–12 months (or PET if transformation suspected); less frequent if stable.
  • Patient education: Report new nodes, B-symptoms, early satiety, bleeding.

Triggers to Initiate Therapy

  • GELF criteria (see Article 154945)
  • POD24 (progression <24 mo after 1L) — high-risk biology
  • Transformation suspicion (rapid growth, LDH↑, new B-symptoms) → biopsy
  • Patient anxiety/preference (valid after informed discussion)

Psychological Support

  • Reframe: "Active monitoring" not "doing nothing."
  • Mindfulness, CBT, peer support (Lymphoma Coalition, FL groups).
  • Clinician validates concern at each visit.

Outcome

~20–30% never require treatment. For those who do, outcomes identical to early-treated. W&W is evidence-based, not neglect.

Lymphoma - Related Articles